Ad
related to: respiratory distress syndrome risk factors in newborns
Search results
Results from the WOW.Com Content Network
Infant respiratory distress syndrome (IRDS), also known as surfactant deficiency disorder (SDD), [2] and previously called hyaline membrane disease (HMD), is a syndrome in premature infants caused by developmental insufficiency of pulmonary surfactant production and structural immaturity in the lungs.
Pleural effusions can also develop, which are also seen with meconium aspiration but not with respiratory distress syndrome. [2] The lungs may also appear hyperinflated. [5] It is a diagnosis of exclusion as it is a benign condition that can have symptoms and signs similar to more serious syndromes, such as respiratory distress or meconium ...
Risk factors include previous ... Infant respiratory distress syndrome is a common complication of neonatal infection, a condition that causes difficulty breathing in ...
Bronchopulmonary dysplasia (BPD; part of the spectrum of chronic lung disease of infancy) is a chronic lung disease which affects premature infants. Premature (preterm) infants who require treatment with supplemental oxygen or require long-term oxygen are at a higher risk. [1]
Other risk factors include infant of a diabetic mother (IDM), method of delivery, fetal asphyxia, genetics, prolonged rupture of membranes (PROM), maternal toxemia, chorioamnionitis, and male sex. The widely accepted pathophysiology of respiratory distress syndrome is it caused by insufficient surfactant production and immature lung and ...
This inability of the newborn to adapt to these changes is caused by various processes, such as: Normal vascular anatomy with functional vasoconstriction: This has a good prognosis, as it is reversible. Causes include hypoxia, meconium aspiration, and respiratory distress syndrome. Left untreated, this can lead to hypoxic respiratory failure ...
The most common use is in premature neonates or babies born with respiratory distress syndrome. Conditions adult respiratory distress syndrome or Hyaline Membrane Disease are also sometimes treated with exogenously derived surfactant. One of the more common uses of surfactant therapy is to treat alveolar surfactant deficiency in premature newborns.
A Cochrane review from 2020 recommends the use of a single course of antenatal corticosteroids to accelerate fetal lung maturation in women at risk of preterm birth. Treatment with antenatal corticosteroids reduces the risk of perinatal death, neonatal death and respiratory distress syndrome and probably reduces the risk of IVH. [128]
Ad
related to: respiratory distress syndrome risk factors in newborns